Cargando…

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy

This manuscript reports on a patient with a metastatic gastrointestinal stromal tumor (GIST) refractory to standard first-line treatment, who underwent a gallium-68 scan based on pre-clinical data of somatostatin receptor (SSTR) expression in such tumors. The gallium-68 DOTATATE scan determined sign...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loaiza-Bonilla, Arturo, Bonilla-Reyes, Paula A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703593/ https://www.ncbi.nlm.nih.gov/pubmed/29188154 http://dx.doi.org/10.7759/cureus.1710

Ejemplares similares

Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study
por: Ebbers, Sander C., et al.
Publicado: (2021)

Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models
por: Ullrich, Martin, et al.
Publicado: (2023)

Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models
por: Zhang, Libo, et al.
Publicado: (2017)

Somatostatin Receptor Theranostics for Refractory Meningiomas
por: Salgues, Betty, et al.
Publicado: (2022)

Somatostatin Receptor Based Imaging and Radionuclide Therapy
por: Xu, Caiyun, et al.
Publicado: (2015)

(68)Gallium- and (90)Yttrium-/(177)Lutetium: “theranostic twins” for diagnosis and treatment of NETs
por: Werner, Rudolf A., et al.
Publicado: (2014)

PET and PET/CT with (68)Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
por: Sollini, Martina, et al.
Publicado: (2014)

In Vivo Evaluation of Gallium-68-Labeled IRDye800CW as a Necrosis Avid Contrast Agent in Solid Tumors
por: Stroet, Marcus C. M., et al.
Publicado: (2021)

Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response
por: Feijtel, Danny, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
por: Ahmadi Bidakhvidi, Niloefar, et al.
Publicado: (2021)

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
por: Shi, Mengqi, et al.
Publicado: (2022)

Subcellular Targeting of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2018)

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
por: Bison, Sander M., et al.
Publicado: (2014)

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
por: Werner, Rudolf A., et al.
Publicado: (2016)

Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors
por: Roden, Anja C., et al.
Publicado: (2022)

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)

Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System
por: Shamsi, Bilal Haider, et al.
Publicado: (2021)

Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT
por: Oh, Sowon, et al.
Publicado: (2011)

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
por: Mileva, Magdalena, et al.
Publicado: (2020)

PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India
por: Sharma, Punit, et al.
Publicado: (2014)

Re-assessing gallium-67 as a therapeutic radionuclide()
por: Othman, Muhamad F. bin, et al.
Publicado: (2017)

Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on (99m)Tc-Octreotide and posttherapeutic (177)Lu-DOTA-TATE scans
por: Amoui, Mahasti, et al.
Publicado: (2021)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
por: Notni, Johannes, et al.
Publicado: (2012)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

1(st) World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
por: Padhy, Ajit Kumar
Publicado: (2011)

68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor
por: Shell, Jasmine, et al.
Publicado: (2018)

Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)

Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up
por: Duan, Heying, et al.
Publicado: (2022)

Somatostatin receptors in the gastrointestinal tract in health and disease.
por: Reubi, J. C.
Publicado: (1992)

Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
por: Librizzi, Damiano, et al.
Publicado: (2023)

Somatostatin Receptor Targeted PET-Imaging for Diagnosis, Radiotherapy Planning and Theranostics of Meningiomas: A Systematic Review of the Literature
por: Filippi, Luca, et al.
Publicado: (2022)

THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience
por: Baum, Richard P., et al.
Publicado: (2012)

A new (68)Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting
por: Mansi, Rosalba, et al.
Publicado: (2020)

Adrenocorticotropic Hormone-Secreting, Subcentimetre Lung Carcinoid Identified by 68Gallium-DOTATATE Positron Emission Tomography Scan
por: Yu, Run
Publicado: (2019)

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
por: Jahn, Ulrika, et al.
Publicado: (2023)

Somatostatin Decorated Quantum Dots for Targeting of Somatostatin Receptors
por: Hafez Abdellatif, Ahmed Abdelfattah, et al.
Publicado: (2018)

Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling
por: Tsionou, Maria Iris, et al.
Publicado: (2017)

The utility of gallium-68 DOTATOC PET/CT in lymphangioleiomyomatosis
por: Gaffney, Brian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dg2sbsoq20padamfg25qjdsi18